Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ales) adjustment in respect of inventories acquired through the acquisition of Transkaryotic Therapies Inc. ("TKT"). Excluding the impact of this fair value adjustment, cost of sales as a percentage of product sales in 2006 was 13% in 2006. The increase in cost of sales as a percentage of product sales in 2007 over 2006 was primarily due to a shift in product mix resulting from increased sales of launched products, which had lower margins than existing products, and the write-off of inventory following the voluntary market withdrawal of a limited quantity of DAYTRANA patches.

For the year to December 31, 2007 cost of sales included a charge of US$5.3 million for share based compensation (2006: US$2.0 million) which included a US$2.1 million cumulative catch up charge (2006: US$nil) in respect of the 2005 option awards, for further information see SG&A below.

Research and development (R&D)

R&D expenditure increased to US$775.2 million for the year to December 31, 2007 (36% of product sales), up from US$295.8 million in the year to December 31, 2006 (19% of product sales).

The increase in R&D expenditure during the year to December 31, 2007 primarily relates to the following:

(i) a non-cash charge of US$100.0 million recognised on the effective settlement of Shire's pre-existing relationship with New River Pharmaceuticals Inc. ("New River"). This charge represents the write-off of capitalised up-front and milestone payments made by Shire prior to the acquisition of New River. This charge is presented within R&D as at the time of the New River acquisition VYVANSE, although approved by the FDA, had not yet received the final scheduling classification from the Drug Enforcement Agency ("DEA") and was therefore not available for commercial sale. Further details in respect of this charge are included in Note 3 of the Financial Statements; and

(ii) an intangible asset impairment charge for the year to December 31, 2007 of US$256.4 mi
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... CITY , Nov. 18, 2014  Great Basin Scientific, ... today announced that the management will host a conference call ... and development programs on Thursday, Nov. 20, at 4:30 pm ... we have made since the Company,s recent IPO and would ... Great Basin,s management," said Ryan Ashton , President and ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today the formation of a ... guidance to the Company as it advances the ... for the treatment of cutaneous T-cell lymphoma (CTCL), ...
(Date:11/15/2014)... Collaborative Consulting, a privately held, employee-based ... of the Boston Globe’s “Top Places to Work 2014”. ... Massachusetts to receive the honor. , The Boston Globe’s ... of their most valuable resource: the people who work ... are based on an array of criteria, including the ...
(Date:11/15/2014)... November 14, 2014 The ... announced today that the society’s Governing Board has ... Edwards Lifesciences chief scientific officer and Dr. Charles ... officer, Abbott Vascular. Mr. Rowe and Dr. ... device development experts. , Dr. Nabil Dib, ...
Breaking Biology Technology:Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders 2
... Group in North America with this Elevated Partner ... ... an Oracle System,Integrator, today announced it has achieved Oracle Certified Advantage,Partner status ... the highest level in the Oracle PartnerNetwork -- BIAS had,to demonstrate superior ...
... for the Long-Term Care Channel, BASKING ... wholly owned subsidiary of Millennium Biotechnologies,Group, Inc. ... the initial,$200,000.00 monthly shipment from Millennium Biotechnologies, ... the previously announced $20,000,000,Five- year exclusive Purchase ...
... Life Sciences R&D to ... Ensure Continued Growth, ... Authority (EDA) announced today that Tris Pharma, Inc. will,expand its ... bonds issued under the state,s Edison Innovation,Fund. Representatives from the ...
Cached Biology Technology:BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 3Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 3Edison Innovation Fund Helps Tris Pharma Expand 2Edison Innovation Fund Helps Tris Pharma Expand 3
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... position is a determinant of antiretroviral treatment effectiveness during ... even among subjects with high rates of drug adherence, ... issue of the Journal of Psychosomatic Research. The ... Harvard School of Public Health (HSPH), Massachusetts General Hospital, ...
... of rotten meat on the premises of a wholesaler in ... grocery stores everywhere is not to be underestimated, the importance ... reliable measurement methods that enable large numbers of samples to ... place in order to make comprehensive monitoring a reality. In ...
... of the GSF National Research Center for Environment ... Centres) the group is continuing to search for cellular ... a prion infection. In collaboration with colleagues from the ... the group used micro-array technologies micro-arrays are ...
Cached Biology News:Socioeconomic position associated with effectiveness of HIV drugs 2New method reveals substances on surfaces of any kind 2Prions and retroviruses -- an unholy alliance? 2
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
Biology Products: